Evening primrose oil is one of the few supplements to have held a UK medicine licence and then lost it, which makes its evidence history unusually clear.
What is evening primrose oil?
Oil pressed from the seeds of Oenothera biennis, a North American plant naturalised across Europe.
The compound of interest is gamma-linolenic acid, an omega 6 fatty acid also found in borage and blackcurrant seed oil.
What do people take it for?
Eczema and dry itchy skin, which was its original licensed indication.
Cyclical breast pain and premenstrual symptoms.
Menopausal hot flushes, which is a more recent marketing direction.
What happened to the licences?
Evening primrose oil products held UK product licences for eczema and breast pain.
Those licences were withdrawn in the early 2000s after a review concluded the evidence did not support efficacy.
The products remained on sale as food supplements, which require no efficacy evidence.
What does the research show?
A Cochrane review of evening primrose oil and borage oil for eczema found no benefit over placebo.
Trials in cyclical breast pain have been mixed, with several finding no advantage.
Evidence for menopausal symptoms is limited and inconsistent.
Why did it seem to work?
Eczema fluctuates considerably, and both breast pain and menopausal symptoms show large placebo responses in trials.
Anything started when symptoms are at their worst will appear to help as they settle.
What are the cautions?
- Possible lowering of the seizure threshold, relevant for anyone with epilepsy
- Effects on bleeding, relevant alongside anticoagulants
- Stopping before surgery
- Avoiding it in pregnancy, given traditional use to ripen the cervix
What are the side effects?
Stomach upset, nausea and headache are the most commonly reported and are generally mild.
What actually helps eczema?
Regular generous use of emollients, topical steroids during flares, identifying triggers and managing the itch scratch cycle.
These have strong evidence and are available on prescription.
What helps cyclical breast pain?
A supportive bra, simple pain relief, and for persistent symptoms a GP assessment, since several options exist.
Any new or persistent breast lump needs prompt assessment regardless.
Is it worth taking?
The evidence does not support the main uses, and evening primrose oil is well tolerated by most people.
Anyone with epilepsy or on anticoagulants should avoid it without advice.
What is the summary?
Evening primrose oil is taken for eczema, breast pain and menopause, lost its UK licences for lack of efficacy, and reviews since have agreed.
This article is general information and not medical advice.
What does this illustrate?
That a product can hold a medicine licence, lose it for lack of efficacy, and continue selling unchanged as a supplement.
The regulatory category changed rather than the product.
Is it a useful omega 6 source?
Omega 6 intake is already high in typical UK diets, so supplementing it is rarely the gap that needs filling.
Omega 3 intake is the one more commonly short.
Who might it suit?
Someone who has found it helpful personally and understands the evidence does not support the main claims.
Anyone with epilepsy or on anticoagulants should avoid it without advice.
What should you check on a label?
The gamma-linolenic acid content, which is the figure that allows comparison between products.
Capsule weight alone does not tell you that.
Is it a useful skin supplement?
Evidence for evening primrose oil improving skin generally is no stronger than for eczema specifically.
Emollients used generously do considerably more for dry skin.
They are also available on prescription for anyone who needs quantity.
Who should avoid it?
Anyone with epilepsy, anyone on anticoagulants, pregnant women and anyone due for surgery.
That is a reasonably broad group for a product with little demonstrated benefit.
A pharmacist can confirm whether it suits your circumstances.
This is one of the clearer cases in which regulatory review reached a conclusion and the market carried on regardless.
The product simply changed category.
Anyone using it should know that.